Efficacy of Biologics in Reducing Exacerbations Requiring Hospitalization or an Emergency Department Visit in Patients with Moderate or Severe, Uncontrolled Asthma.

Mepolizumab demonstrated a numerical trend of reducing the AAER; however, two out of the three mepolizumab studies (MUSCA and DREAM) had upper 95% CIs of greater than or equal to 1 and therefore did not demonstrate a reduction in the AAER compared with placebo [AAER ratios (95% CI): 0.31 (0.08–1.24) and 0.61 (0.28–1.33), respectively] [ 16 , 22 ].

also in 1,012 other papers